Dr David Gillen (BSc MBBS MFPM MRCGP) is the UK Medical Director for Pfizer and from January 2009 will be moving to a new role as Head of Medical for the Pfizer Primary Care Business Unit covering Europe, Canada, Australia and New Zealand. David qualified in Medicine from St Mary’s hospital in 1992. During his undergraduate medical training, as well as being a Clegg Scholar to the BMJ during his elective, he completed a BSc in Physiology and Clinical Pharmacology. He retained this interest in Pharmaceutical Medicine during his postgraduate training in Medicine, Cardiology and General Practice and joined Pfizer Global Research and Development in Sandwich in 1998. At Pfizer David has worked in R and D, in Medical Affairs for the UK and Globally in New York for 4 years. He rejoined Pfizer UK in April 2007 having spent 2 years at Wyeth UK as Medical Director from 2005. He currently leads a team colleagues in a diverse Medical Department which includes functions such as Medical Affairs, Clinical Research, Drug Safety, Regulatory and Medical Information..  David is active in the UK Clinical Research community, serves on sub- committees of the ABPI, NICE and UKCRC and was a member of the RCP working party looking at the relationship between Industry, Academic Medicine and the NHS.

Competing interests

1) Have you in the past five years accepted the following from an organisation that may in any way gain or lose financially from the results of your study or the conclusions of your review, editorial, or letter?

a) Reimbursement for attending a symposium?
AWAITING INFORMATION
b) A fee for speaking?
AWAITING INFORMATION
c) A fee for organising education?
AWAITING INFORMATION
d) Funds for research?
AWAITING INFORMATION
e) Funds for a member of staff?
AWAITING INFORMATION
f) Fees for consulting?
AWAITING INFORMATION

2) Have you in the past five years been employed by an organisation that may in any way gain or lose financially from the results of your study or the conclusions of your review, editorial, or letter?
AWAITING INFORMATION

3) Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the results of your study or the conclusions of your review, editorial, or letter?
AWAITING INFORMATION

4) Have you acted as an expert witness on the subject of your study, review, editorial, or letter?
AWAITING INFORMATION

5) Do you have any other competing financial interests? If so, please specify.
AWAITING INFORMATION